📊 INBS Key Takeaways
Is Intelligent Bio Solutions Inc.. (INBS) a Good Investment?
INBS operates with a fundamentally broken business model, losing $8.6M on just $3.1M in revenue while burning $8.7M annually in operating cash. With only $6.9M in cash reserves, the company faces approximately 9 months of runway before requiring dilutive financing or strategic intervention. While healthy gross margins suggest product viability, the inability to scale revenue or control costs makes the current path unsustainable.
Fundamentals show contracting revenue, deeply negative margins, and persistent cash burn that far exceeds the company’s modest cash balance, implying a short runway and likely need for external financing. While gross margins are acceptable and leverage is low, the current scale is insufficient to cover operating costs, and profitability improvements are minimal.
Intelligent Bio Solutions Inc.. Key Strengths (INBS)
- Healthy gross margin of 49.3% demonstrates core product has market value and pricing power
- Strong liquidity position with current ratio of 2.11x and $6.9M cash reserves
- Conservative leverage at 0.18x debt-to-equity provides financial flexibility for restructuring
- Decent gross margin (~49%) suggests viable unit economics at scale
- Low leverage (Debt/Equity ~0.15x) reduces insolvency risk from debt
- Solid current and quick ratios indicate near-term solvency
INBS Stock Risks: Intelligent Bio Solutions Inc.. Investment Risks
- Catastrophic cash burn of $8.7M annually against $6.9M liquid reserves implies ~9 months operational runway
- Operating losses of -$8.6M dwarf $3.1M revenue, indicating structural unprofitability not attributable to scale inefficiencies
- Minimal revenue base suggests early-stage or severely struggling operations with unproven market traction in competitive medical devices sector
- Sustained operating losses and FCF burn with limited cash (~$0.74M)
- Revenue decline (-1.9% YoY) raises execution and demand concerns
- High dilution/going-concern risk if additional capital is required
Key Metrics to Watch
- Quarterly revenue growth trajectory and path to positive operating cash flow
- Monthly cash burn rate and sufficiency of reserves without external financing
- Gross margin sustainability and operating expense control as business attempts to scale
- Quarterly revenue growth (YoY/QoQ)
- Operating cash flow (burn) vs cash balance/runway
Intelligent Bio Solutions Inc.. (INBS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.11x current ratio provides a solid financial cushion.
INBS Profit Margin, ROE & Profitability Analysis
INBS vs Healthcare Sector: How Intelligent Bio Solutions Inc.. Compares
How Intelligent Bio Solutions Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Intelligent Bio Solutions Inc.. Stock Overvalued? INBS Valuation Analysis 2026
Based on fundamental analysis, Intelligent Bio Solutions Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Intelligent Bio Solutions Inc.. Balance Sheet: INBS Debt, Cash & Liquidity
INBS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Intelligent Bio Solutions Inc..'s revenue has grown significantly by 57% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.38 indicates the company is currently unprofitable.
INBS Revenue Growth, EPS Growth & YoY Performance
INBS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $728.9K | -$2.5M | $-1.80 |
| Q2 2026 | $607.5K | -$2.2M | $-2.82 |
| Q1 2026 | $872.3K | -$2.7M | $-0.35 |
| Q3 2025 | $728.9K | -$2.5M | $-0.44 |
| Q2 2025 | $607.5K | -$2.0M | $-0.50 |
| Q1 2025 | $796.1K | -$2.4M | $-0.70 |
| Q3 2024 | $457.1K | -$3.0M | $-1.43 |
| Q2 2024 | $356.7K | -$420.6K | $-2.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Intelligent Bio Solutions Inc.. Dividends, Buybacks & Capital Allocation
INBS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Intelligent Bio Solutions Inc.. (CIK: 0001725430)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INBS
What is the AI rating for INBS?
Intelligent Bio Solutions Inc.. (INBS) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INBS's key strengths?
Claude: Healthy gross margin of 49.3% demonstrates core product has market value and pricing power. Strong liquidity position with current ratio of 2.11x and $6.9M cash reserves. ChatGPT: Decent gross margin (~49%) suggests viable unit economics at scale. Low leverage (Debt/Equity ~0.15x) reduces insolvency risk from debt.
What are the risks of investing in INBS?
Claude: Catastrophic cash burn of $8.7M annually against $6.9M liquid reserves implies ~9 months operational runway. Operating losses of -$8.6M dwarf $3.1M revenue, indicating structural unprofitability not attributable to scale inefficiencies. ChatGPT: Sustained operating losses and FCF burn with limited cash (~$0.74M). Revenue decline (-1.9% YoY) raises execution and demand concerns.
What is INBS's revenue and growth?
Intelligent Bio Solutions Inc.. reported revenue of $3.1M.
Does INBS pay dividends?
Intelligent Bio Solutions Inc.. does not currently pay dividends.
Where can I find INBS SEC filings?
Official SEC filings for Intelligent Bio Solutions Inc.. (CIK: 0001725430) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INBS's EPS?
Intelligent Bio Solutions Inc.. has a diluted EPS of $-7.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is INBS's fundamental grade?
Based on our AI fundamental analysis in May 2026, Intelligent Bio Solutions Inc.. has a D grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is INBS stock overvalued or undervalued?
Valuation metrics for INBS: ROE of -95.1% (sector avg: 15%), net margin of -277.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is INBS's AI grade for 2026?
Our dual AI analysis gives Intelligent Bio Solutions Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INBS's free cash flow?
Intelligent Bio Solutions Inc..'s operating cash flow is $-8.7M, with capital expenditures of $125.7K. FCF margin is -289.0%.
How does INBS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -277.7% (avg: 12%), ROE -95.1% (avg: 15%), current ratio 2.11 (avg: 2).